Connecta Therapeutics raises €1.7 M to develop new treatment for fragile X syndrome

by Parc Científic de Barcelona

Connecta Therapeutics has closed a €1.7 million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have frag...

Read more

Connecta Therapeutics raises €1.7 M in a round led by Inveready to develop new treatment for fragile X syndrome

by Inveready

Connecta Therapeutics has closed a €1.7 million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have frag...

Read more
Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Palobiofarma announces the completion th...

by Palobiofarma

Palobiofarma S.L. is pleased to announce the “last patient last visi...

Photos Stream